Evaluate the Impact of Afatinib on Quality of Life and Symptom Burden of Greek Subjects With Advanced NSCLC in Routine Patient Care Settings

NCT02440854 · clinicaltrials.gov ↗

COMPLETED

Status

80

Enrollment

INDUSTRY

Sponsor class

Conditions

Carcinoma, Non-Small-Cell Lung

Interventions

DRUG: afatinib

Sponsor

Boehringer Ingelheim